Discovery Pharma Consulting

Dr. Lars Knutsen is an internationally recognized scientist, and has contributed greatly to the success of companies he has been involved with, working in three countries and on two continents.  He has extensive experience within all the phases of Drug Discovery up to and including Preclinical Development, evidenced by the five drugs he has been closely involved with that have moved forward to the market and to clinical trials. Gabitril™ is marketed for Epilepsy, and the A2A antagonist BIIB014/V2006 has recently shown Phase IIa Proof of Concept in Parkinson’s Disease with Biogen Idec.

Lars was appointed an Adjunct Professor at the Department of Pharmacology, Drexel University College of Medicine in Philadelphia, PA in 2009 and participates in teaching a course in Drug Discovery.  He has an excellent publication record in Drug Discovery with an outstanding knowledge of Intellectual Property as applied to Drug Research, Pharmacokinetics (PK) as well as Absorption, Distribution, Metabolism and Excretion (ADME) and has completed training in these fields as well as Research Management training modules.  Lars is in demand as an Opinion Leader in Drug Discovery and as a Chairman and Speaker at International Conferences. He is a regular reviewer for J. Med. Chem. and Bioorg. Med. Chem. Lett.  Lars was raised in England, of Norwegian parents, and is a US Permanent Resident.  He can therefore consult in North America and Europe.